Back to CVE records
High 8.8Published May 29, 2026

CVE-2026-5768The Frontier X2 device allows unauthenticated BLE read/write access to critical GATT characteristics without enforcing pairing authentication or authorization.

Updated under an hour ago ()

Does this affect you?

It lists no affected products yet. Add what you run and Signals checks it as products are added.

No exploitation reported and no EPSS estimate yet.

The Frontier X2 device allows unauthenticated BLE read/write access to critical GATT characteristics without enforcing pairing authentication or authorization. This allows attackers within BLE range to perform unauthorized control of device functions, including starting/stopping activities, triggering vibrations, causing denial-of-service conditions, and fuzzing characteristic values to induce unexpected behavior. Additionally, the Frontier X mobile application lacks proper BLE device authentication, allowing attackers to impersonate a legitimate Frontier X2 device and connect to the application. By cloning BLE advertisements and exposing expected GATT characteristics, attackers can manipulate activity states and inject fabricated health telemetry such as breathing rate, heart rate, strain, and other health-related data into the mobile application.

CVSS
8.8 HIGH (v3.1, NVD)CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
Weakness (CWE)
CWE-306
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Not given
NVD analysis
Deferred
Record last updated
Jul 22, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

No affected products are listed yet.

References

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.